Second Vir-GSK monoclonal antibody to enter Phase 1/2 COVID-19 trials
Vir Biotechnology and GSK will evaluate VIR-7832 in the early treatment of COVID-19 in a Phase 1b/2a trial starting in the first quarter of this year.
Archives for January 14, 2021
Samsung Biologics: ‘Our next decade will be marked by increased expansion and portfolio diversification’
Samsung Biologics is aiming to become ‘a full-service biopharmaceutical company’: creating a greater global footprint for its CDMO business, continuing to advance its biosimilars business, and laying the groundwork for novel drug development.
Pfizer backing biotechnology innovation with $120m capital outlay
Pfizer is investing US$25m in a US developer of live biotherapeutics, Vedanta Biosciences.